What is NewAmsterdam Pharma Company N.V.'s (NAMS) StockRank?

MoatMap's StockRank for NewAmsterdam Pharma Company N.V. (NAMS) is 9/100, with a Strong Sell signal. This is a composite score combining Quality (31), Value (23), and Momentum (27) factor ranks across MoatMap's 20,000+ stock universe.

Does NewAmsterdam Pharma Company N.V. have an economic moat?

NewAmsterdam Pharma Company N.V. (NAMS) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is NewAmsterdam Pharma Company N.V. a buy, hold, or sell?

MoatMap's current signal for NewAmsterdam Pharma Company N.V. (NAMS) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is NewAmsterdam Pharma Company N.V. in?

NewAmsterdam Pharma Company N.V. (NAMS) operates in the Healthcare sector, specifically the Biotechnology industry (Netherlands).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

NAMS

Strong Sell

NewAmsterdam Pharma Company N.V. · Healthcare · Netherlands · $3.0B · Avg Vol: $29M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-36.8%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for cholesterol management and cardiovascular disease. Its lead program, obicetrapib, targets CETP inhibition, offering a potentially differentiated mechanism of action with broad applicability. The company's innovative approach aims to address significant unmet needs in dyslipidemia, providing a strong growth opportunity in the pharmaceutical landscape.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	102.7M	14.1M	45.6M	22.5M	-39.7%	7.1M	29.1M	—	29.4%
EPS	-1.19	-2.15	-2.56	-1.78	—	-2.16	-1.66	-1.53	—
Shares	81.6M	82.5M	108.1M	114.4M	+40.3%	116.9M	—	—	—
Debt	0.1M	60.0K	0.4M	0.2M	17.0%	82.0K	—	—	—
Equity	430.1M	288.4M	757.5M	683.4M	16.7%	—	—	—	—
Op CF	10.7M	-141.2M	-158.6M	-147.8M	—	-143.5M	—	—	—
Inv CF	-0.2M	-24.0K	-62.8M	-174.9M	—	—	—	—	—
Fin CF	391.9M	8.9M	659.5M	29.5M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)-12.7%

SMA 50SMA 200

$25.90

RSI (14)

36.4

52W High

$42.21

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-35.8%22.2

ROE

-36.8%23.9

GP/Assets

0.9%13.3

Op. Margin

-1752.6%5.9

FCF/Assets

-18.7%23.0

Piotroski

322.6

Int. Cover

—N/A

D/E Ratio

0.00x95.6

Current Ratio

9.03x84.5

Value

P/E (TTM)

—N/A

EV/EBITDA

-10.8x25.0

P/FCF

—N/A

P/B

5.1x27.7

P/S

449.8x3.5

Div Yield

—N/A

Momentum

52W High %

61%37.2

RS 6M

-40%22.3

SMA 50/200

0.92x40.5

EPS Rev 4W

-22.0%4.0

EPS Rev 12W

-21.7%6.6

EPS Improve

+27%40.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$3.0B

P/E (Forward)

-17.4x

Gross Margin

100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NAMS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
NAMS	NewAmsterdam Pharma Company N.V.(you)	$3.0B	9	Strong Sell
QURE	uniQure N.V.	$3.4B	18	Strong Sell
PHARM.AS	Pharming Group N.V.	$815M	36	Hold
ONWD.BR	Onward Medical N.V.	$199M	4	Strong Sell
PRQR	ProQR Therapeutics N.V.	$323M	30	Sell
ARGX	argenx SE	$63.6B	75	Buy
RDC.DE	Redcare Pharmacy NV	$1.5B	54	Hold
QGEN	Qiagen N.V.	$8.9B	65	Buy
PHG	Koninklijke Philips N.V.	$26.1B	84	Strong Buy

Peer medians: ROE 10.2% · P/E 22.2x · Gross margin 66.4%

NewAmsterdam Pharma Company N.V. (NAMS): Stock Score Summary

NewAmsterdam Pharma Company N.V. (NAMS) has a MoatMap StockRank of 9/100 based on Quality (31/100), Value (23/100), and Momentum (27/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$25.90
Market Cap	$3.0B
P/E (Forward)	-17.43
Price/Book	5.11
Return on Equity	-36.8%
Return on Invested Capital	-35.8%
Debt/Equity	0.00x
Gross Margin	100.0%
Operating Margin	-1752.6%
Revenue Growth	-80.7%
Free Cash Flow	$-144M

NewAmsterdam Pharma Company N.V. operates in the Biotechnology industry, part of the Healthcare sector (Netherlands).

Frequently Asked Questions

What is NewAmsterdam Pharma Company N.V.’s (NAMS) StockRank?: MoatMap’s StockRank for NewAmsterdam Pharma Company N.V. (NAMS) is 9/100, with a Strong Sell signal. It is a composite of Quality (31), Value (23), and Momentum (27) factor ranks across MoatMap’s 20,000+ stock universe.
Does NewAmsterdam Pharma Company N.V. have an economic moat?: NewAmsterdam Pharma Company N.V. (NAMS) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is NewAmsterdam Pharma Company N.V. a buy, hold, or sell?: MoatMap’s current signal for NewAmsterdam Pharma Company N.V. (NAMS) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is NewAmsterdam Pharma Company N.V. in?: NewAmsterdam Pharma Company N.V. (NAMS) operates in the Healthcare sector, specifically the Biotechnology industry (Netherlands).